Literature DB >> 35294663

Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer's disease.

Xian Zhou1, Madhuri Venigalla2, Ritesh Raju2, Gerald Münch3.   

Abstract

Prof. Dr. Peter Riederer, the former Head of the Neurochemistry Department of the Psychiatry and Psychotherapy Clinic at the University of Würzburg (Germany), has been one of the pioneers of research into oxidative stress in Parkinson's and Alzheimer's disease (AD). This review will outline how his scientific contribution to the field has opened a new direction for AD treatment beyond "plaques and tangles". In the 1990s, Prof. Riederer was one of the first scientists who proposed oxidative stress and neuroinflammation as one of the major contributors to Alzheimer's disease, despite the overwhelming support for the "amyloid-only" hypothesis at the time, which postulated that the sole and only cause of AD is β-amyloid. His group also highlighted the role of advanced glycation end products, sugar and dicarbonyl-derived protein modifications, which crosslink proteins into insoluble aggregates and potent pro-inflammatory activators of microglia. For the treatment of chronic neuroinflammation, he and his group suggested that the most appropriate drug class would be cytokine-suppressive anti-inflammatory drugs (CSAIDs) which have a broader anti-inflammatory action range than conventional non-steroidal anti-inflammatory drugs. One of the most potent CSAIDs is curcumin, but it suffers from a variety of pharmacokinetic disadvantages including low bioavailability, which might have tainted many human clinical trials. Although a variety of oral formulations with increased bioavailability have been developed, curcumin's absorption after oral delivery is too low to reach therapeutic concentrations in the micromolar range in the systemic circulation and the brain. This review will conclude with evidence that rectally applied suppositories might be the best alternatives to oral medications, as this route will be able to evade first-pass metabolism in the liver and achieve high concentrations of curcumin in plasma and tissues, including the brain.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Brain; Curcumin; Dementia; Glycation; Inflammation; Suppositories

Mesh:

Substances:

Year:  2022        PMID: 35294663     DOI: 10.1007/s00702-022-02480-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.850


  92 in total

1.  Microglia, amyloid and dementia in alzheimer disease. A correlative study.

Authors:  Y M Arends; C Duyckaerts; J M Rozemuller; P Eikelenboom; J J Hauw
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

2.  Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E.

Authors:  K R Bales; Y Du; D Holtzman; B Cordell; S M Paul
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

3.  Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease.

Authors:  Larry Baum; Christopher Wai Kei Lam; Stanley Kwok-Kuen Cheung; Timothy Kwok; Victor Lui; Joshua Tsoh; Linda Lam; Vivian Leung; Elsie Hui; Chelsia Ng; Jean Woo; Helen Fung Kum Chiu; William B Goggins; Benny Chung-Ying Zee; King Fai Cheng; Carmen Yuet Shim Fong; Adrian Wong; Hazel Mok; Moses Sing Sum Chow; Ping Chuen Ho; Siu Po Ip; Chung Shun Ho; Xiong Wen Yu; Caroline Yau Lin Lai; Ming-Houng Chan; Samuel Szeto; Iris Hiu Shuen Chan; Vincent Mok
Journal:  J Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.153

Review 4.  Review: activation patterns of microglia and their identification in the human brain.

Authors:  D Boche; V H Perry; J A R Nicoll
Journal:  Neuropathol Appl Neurobiol       Date:  2013-02       Impact factor: 8.090

5.  Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population.

Authors:  Katherine H M Cox; Andrew Pipingas; Andrew B Scholey
Journal:  J Psychopharmacol       Date:  2014-10-02       Impact factor: 4.153

6.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

Review 7.  Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease.

Authors:  I A Clark; B Vissel
Journal:  Br J Pharmacol       Date:  2015-06-29       Impact factor: 8.739

8.  Profiling Microglia From Alzheimer's Disease Donors and Non-demented Elderly in Acute Human Postmortem Cortical Tissue.

Authors:  Astrid M Alsema; Qiong Jiang; Laura Kracht; Emma Gerrits; Marissa L Dubbelaar; Anneke Miedema; Nieske Brouwer; Elly M Hol; Jinte Middeldorp; Roland van Dijk; Maya Woodbury; Astrid Wachter; Simon Xi; Thomas Möller; Knut P Biber; Susanne M Kooistra; Erik W G M Boddeke; Bart J L Eggen
Journal:  Front Mol Neurosci       Date:  2020-10-28       Impact factor: 5.639

Review 9.  Insights into T-cell dysfunction in Alzheimer's disease.

Authors:  Linbin Dai; Yong Shen
Journal:  Aging Cell       Date:  2021-11-01       Impact factor: 9.304

View more
  1 in total

1.  Dual Mechanism of Action of Curcumin in Experimental Models of Multiple Sclerosis.

Authors:  Ines ELBini-Dhouib; Maroua Manai; Nour-Elhouda Neili; Soumaya Marzouki; Ghada Sahraoui; Warda Ben Achour; Sondes Zouaghi; Melika BenAhmed; Raoudha Doghri; Najet Srairi-Abid
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.